Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 3/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21222221 | 0.90 | ALDH1A1 (0.41) | HRH3ALDH1A1TEAD1EPHX2 | |
| SCHEMBL16253364 | 0.88 | CA1 (0.39) | HRH3ALDH1A1TEAD1KDM5ASLC6A5 | |
| SCHEMBL26088623 | 0.82 | HRH3 (0.50) | HRH3ALDH1A1SLC6A5MCHR1 | |
| SCHEMBL16253370 | 0.81 | CTSK (0.54) | KDM4D | |
| SCHEMBL13860513 | 0.79 | TEAD1 (0.33) | HRH3ALDH1A1TEAD1SLC6A5KDM4D | |
| SCHEMBL16253367 | 0.78 | HRH4 (0.33) | — | |
| SCHEMBL13860500 | 0.77 | HRH3 (0.33) | HRH3TEAD1KDM5ASLC6A5MCHR1 | |
| SCHEMBL16253369 | 0.77 | — | — | |
| SCHEMBL13740190 | 0.76 | ALDH1A1 (0.36) | HRH3ALDH1A1MCHR1KDM4D | |
| SCHEMBL13860515 | 0.75 | SLC6A5 (0.31) | HRH3TEAD1SLC6A5CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492397-B2 | Aminopyridine derivatives having Aurora A selective inhibitory action | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120029004-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | BANYU PHARMACEUTICALS CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029004-A1 | NOVEL AMINOPYRIDINE DERIVATIVES HAVING AURORA A SELECTIVE INHIBITORY ACTION | AURKA, AURKC, AURKB | HRH3 51/4885ALDH1A1 2363/4885TEAD1 2670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.